查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1871569

腫瘤和血液學分子檢測市場報告：趨勢、預測和競爭分析（至2031年）

Onco-Hematology Molecular Testing Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球腫瘤和血液分子檢測市場前景廣闊，主要得益於國家級參考/專科檢查室、大學附屬檢查室和社區醫院市場的發展機會。預計2025年至2031年，全球腫瘤和血液分子檢測市場將以6.5%的複合年成長率成長。推動該市場成長的關鍵因素包括：對個人化醫療和標靶治療日益成長的需求，以及分子檢測技術的進步，這些進步提高了診斷的準確性。

  • 根據 Lucintel 的預測，按類型分類，國家參考檢查室預計在預測期內仍將是最大的細分市場。
  • 根據應用情況來看，國家參考檢查室/專業檢查室預計將呈現更高的成長率。
  • 從區域來看，預計亞太地區在預測期內將達到最高的成長率。

腫瘤和血液分子檢測市場的最新趨勢

全球腫瘤和血液學分子檢測市場受到多種新興趨勢的驅動，這些趨勢正在塑造未來診斷和治療策略。這些趨勢凸顯了技術進步、精準醫療和個人化醫療的發展。

  • 次世代定序（NGS）技術的進步：NGS技術徹底改變了分子檢測，能夠檢測骨髓惡性腫瘤中多種基因突變。這項技術可以進行全面的基因分析，從而深入了解預後、疾病進展和治療反應，最終為血液系統癌症患者提供更個人化的治療。
  • 液態生物檢體簡介：液態生物檢體作為一種非侵入性替代傳統切片檢查的方法，正日益普及。它可以透過血液樣本檢測基因突變和改變，從而更容易監測疾病進展和治療反應，尤其是在白血病等血液癌症的治療中，傳統切片檢查方法在這些疾病的治療中更具挑戰性。
  • 標靶治療的整合：分子檢測在識別標靶治療的生物標記和提高治療效果方面發揮關鍵作用。針對特定基因突變的標靶治療越來越受歡迎，因為它們可以最大限度地減少副作用並改善治療效果，尤其是在淋巴瘤和骨髓瘤等血液癌症患者中。
  • 人工智慧和機器學習在診斷中的應用：人工智慧 (AI) 和機器學習在分子檢測中的應用正在提高診斷準確性。人工智慧正被用於快速分析基因數據，從而實現骨髓惡性腫瘤的早期檢測和個人化治療方案的製定，最終有助於改善臨床決策。
  • 擴大檢測覆蓋範圍：新興市場醫療服務可近性的改善正在推動腫瘤和分子血液檢測的普及。各國政府、醫療機構和診斷公司正攜手合作，致力於降低這些先進檢測技術的成本，提高其可近性，從而在資源匱乏地區實現早期診斷和改善治療效果。

全球腫瘤和血液學分子檢測市場的新興趨勢正在改變診斷、治療方法和患者照護。從次世代定序和液態生物檢體的興起，到人工智慧和標靶治療的整合，這些趨勢正使個人化、非侵入性診斷更加普及和精準。這些技術的日益普及有望改善患者預後，並推動腫瘤血液學檢測領域的重大進步。

腫瘤和血液分子檢測市場的最新趨勢

全球腫瘤和血液學分子檢測市場的最新發展反映了提高診斷準確性和改善患者預後的持續努力。這些發展是由技術創新和對個人化醫療日益成長的需求所驅動的。

  • 美國食品藥物管理局（FDA）核准多種分子診斷工具：在美國，多種用於血液癌症的分子診斷工具已獲得FDA核准，從而能夠更早發現癌症並改善治療監測。這些核准進一步凸顯了分子檢測在血液癌症管理中的重要性，並為在臨床實踐中採用更先進的技術鋪平了道路。
  • 液態生物檢體在血液癌症檢測中的應用：液態生物檢體的廣泛應用正在改變血液癌症的診斷和後續觀察。液態生物檢體使臨床醫生能夠利用血液樣本追蹤基因突變和疾病進展，為白血病和淋巴瘤患者提供了一種微創便捷的檢測選擇。
  • 次世代定序(NGS) 平台的技術進步：更精準、更經濟的 NGS 平台的開發，正使分子檢測在全球範圍內更加普及。 NGS 能夠更有效地識別罕見突變和基因改變，提供全面的基因組數據，從而實現精準醫療，改善血液腫瘤患者的治療效果。
  • 攜手提升檢測可及性：醫療服務提供者、診斷公司和政府機構之間加強合作，正在改善已開發國家和開發中國家分子檢測的可及性。這些夥伴關係旨在降低分子檢測技術的成本，使其惠及更多患者。
  • 人工智慧在分子檢測數據分析中的應用：人工智慧正被整合到分子檢測平台中，以更有效率地分析複雜的基因數據。透過提高數據解讀的速度和準確性，人工智慧正在幫助臨床醫生就治療方案和疾病監測做出更明智的決策。

這些關鍵進展正對全球腫瘤和血液學分子檢測市場產生深遠影響。從核准和液態生物檢體的普及，到次世代定序（NGS）技術的進步和人工智慧的整合，這些創新正在提升診斷能力，實現更個人化的治療，並拓展分子檢測的應用範圍。這些進展共同預示著腫瘤和血液學醫療保健將迎來一個更精準、便利的未來。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球腫瘤和血液分子檢測市場（按類型分類）

  • 概述
  • 吸引力分析：按類型
  • qPCR：趨勢與預測（2019-2031）
  • dPCR：趨勢與預測（2019-2031）
  • 次世代定序：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031 年）

5. 全球腫瘤和血液分子檢測市場（按應用分類）

  • 概述
  • 吸引力分析：依目的
  • 國家檢查室/專業檢查室：趨勢與預測（2019-2031）
  • 大學醫院：趨勢與預測（2019-2031 年）
  • 社區醫院：趨勢與預測（2019-2031 年）

第6章 區域分析

  • 概述
  • 全球腫瘤和血液分子檢測市場（按地區分類）

7. 北美腫瘤與血液分子檢測市場

  • 概述
  • 北美腫瘤和血液分子檢測市場（按類型分類）
  • 北美腫瘤和血液分子檢測市場按應用領域分類
  • 美國腫瘤與血液分子檢測市場
  • 墨西哥腫瘤和血液分子檢測市場
  • 加拿大腫瘤和血液分子檢測市場

8. 歐洲腫瘤和血液分子檢測市場

  • 概述
  • 歐洲腫瘤和血液學分子檢測市場（按類型分類）
  • 歐洲腫瘤和血液分子檢測市場按應用領域分類
  • 德國腫瘤與血液分子檢測市場
  • 法國腫瘤與血液學分子檢測市場
  • 西班牙腫瘤和血液學分子檢測市場
  • 義大利腫瘤和血液分子檢測市場
  • 英國腫瘤與血液分子檢測市場

9. 亞太地區腫瘤與血液學分子檢測市場

  • 概述
  • 亞太地區腫瘤和血液學分子檢測市場（按類型分類）
  • 亞太地區腫瘤和血液分子檢測市場（按應用分類）
  • 日本腫瘤與血液分子檢測市場
  • 印度腫瘤和血液分子檢測市場
  • 中國腫瘤與血液分子檢測市場
  • 韓國腫瘤和血液分子檢測市場
  • 印尼腫瘤與血液分子檢測市場

10. 世界其他地區（ROW）腫瘤和血液學分子檢測市場

  • 概述
  • ROW腫瘤和血液分子檢測市場按類型分類
  • ROW腫瘤和血液分子檢測市場按應用領域分類
  • 中東腫瘤與血液學分子檢測市場
  • 南美洲腫瘤和血液分子檢測市場
  • 非洲腫瘤與血液學分子檢測市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市佔率分析

第12章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按類型分類的成長機會
    • 透過申請獲得發展機會
  • 全球腫瘤和血液學分子檢測市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 企業合併、協議、合作關係和合資企業

第13章：價值鏈中主要企業的概況

  • 競爭分析
  • Asuragen
  • Bio-Rad Laboratories
  • Illumina
  • QIAGEN
  • Cepheid

第14章附錄

  • 圖表清單
  • 表格列表
  • 分析方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於 Lucintel
  • 詢問

The future of the global onco-hematology molecular testing market looks promising with opportunities in the national reference lab / specialty lab, university hospital, and community hospital markets. The global onco-hematology molecular testing market is expected to grow with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are the growing demand for personalized medicine and targeted therapies and the advancements in molecular testing technologies enabling better diagnostic accuracy.

  • Lucintel forecasts that, within the type category, national reference lab will remain the largest segment over the forecast period.
  • Within the application category, national reference lab/ specialty labs is expected to witness the higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Onco-Hematology Molecular Testing Market

The global market for onco-hematology molecular testing is driven by several emerging trends that are shaping the future of diagnostics and treatment strategies. These trends highlight advancements in technology, precision medicine, and personalized care.

  • Next-Generation Sequencing (NGS) Advancements: NGS technology is revolutionizing molecular testing, enabling the detection of a wide range of genetic mutations in hematologic malignancies. This technology allows for comprehensive genetic profiling, offering insights into prognosis, disease progression, and treatment response, leading to more personalized care for patients with blood cancers.
  • Liquid Biopsy Adoption: Liquid biopsy is gaining traction as a non-invasive alternative to traditional biopsy methods. It enables the detection of genetic mutations and alterations through blood samples, making it easier to monitor disease progression and treatment efficacy. Liquid biopsy is particularly valuable for managing hematologic cancers like leukemia, where traditional biopsy methods may be challenging.
  • Targeted Therapy Integration: Molecular testing plays a critical role in identifying biomarkers for targeted therapies, enhancing treatment efficacy. Targeted treatments tailored to specific genetic mutations are gaining popularity, as they help minimize side effects and improve patient outcomes, particularly for patients with hematologic cancers like lymphoma and myeloma.
  • AI and Machine Learning in Diagnostics: The integration of artificial intelligence (AI) and machine learning in molecular testing is enhancing diagnostic accuracy. AI is being used to analyze genetic data quickly, enabling earlier detection of hematologic malignancies and the identification of personalized treatment plans, ultimately improving clinical decision-making.
  • Expansion of Testing Access: Increasing healthcare access in emerging markets is leading to the wider adoption of onco-hematology molecular testing. Governments, healthcare providers, and diagnostic companies are working together to make these advanced testing technologies more affordable and accessible, ultimately improving early diagnosis and treatment outcomes in underserved regions.

Emerging trends in the global onco-hematology molecular testing market are reshaping diagnostics, treatment approaches, and patient care. From the rise of next-generation sequencing and liquid biopsies to the integration of AI and targeted therapies, these trends are making personalized, non-invasive diagnostics more accessible and precise. The growing adoption of these technologies is set to improve patient outcomes and drive significant advancements in onco-hematology testing.

Recent Developments in the Onco-Hematology Molecular Testing Market

Recent advancements in the global onco-hematology molecular testing market reflect ongoing efforts to improve diagnostic accuracy and patient outcomes. These developments are driven by technological innovations and increased demand for personalized medicine.

  • FDA Approvals for Molecular Diagnostic Tools: In the U.S., several molecular diagnostic tools for hematologic cancers have received FDA approval, enabling better early detection and treatment monitoring. These approvals validate the importance of molecular testing in managing blood cancers, and they open the door for more advanced technologies in clinical practice.
  • Adoption of Liquid Biopsy in Hematologic Cancer Testing: The widespread use of liquid biopsy is transforming how hematologic cancers are diagnosed and monitored. Liquid biopsy allows clinicians to track mutations and disease progression using blood samples, which is particularly useful for patients with leukemia or lymphoma, offering a less invasive and more convenient testing method.
  • Technological Advancements in NGS Platforms: The development of more accurate and cost-effective NGS platforms is making molecular testing more accessible globally. With enhanced capabilities to identify rare mutations and genetic changes, NGS is enabling precision medicine and improving treatment outcomes for patients with hematologic cancers by providing comprehensive genomic data.
  • Collaborations to Improve Testing Access: Increased collaboration between healthcare providers, diagnostic companies, and government agencies is improving the accessibility of molecular testing in both developed and developing countries. These partnerships are focusing on making molecular testing technologies affordable and available to a wider patient population.
  • Integration of AI in Data Analysis for Molecular Testing: Artificial intelligence is being integrated into molecular testing platforms to analyze complex genetic data more efficiently. By improving the speed and accuracy of data interpretation, AI is helping clinicians make more informed decisions about treatment plans and disease monitoring.

These key developments are having a profound impact on the global onco-hematology molecular testing market. From FDA approvals and the growth of liquid biopsy to NGS advancements and AI integration, these innovations are improving diagnostic capabilities, enabling more personalized treatment, and expanding the reach of molecular testing. Together, they signal a future of more precise and accessible onco-hematology care.

Strategic Growth Opportunities in the Onco-Hematology Molecular Testing Market

The global onco-hematology molecular testing market is filled with growth opportunities in various applications. These opportunities reflect the continued demand for advanced diagnostic tools and treatments tailored to hematologic malignancies.

  • NGS for Precision Diagnosis: Next-generation sequencing (NGS) is becoming a critical tool for diagnosing hematologic cancers. By providing comprehensive insights into genetic mutations, NGS enables more precise diagnoses, better monitoring of disease progression, and personalized treatment plans, offering significant growth potential in both developed and emerging markets.
  • Liquid Biopsy for Non-Invasive Testing: The adoption of liquid biopsy technology is a key growth opportunity in onco-hematology testing. Liquid biopsy is gaining acceptance as a non-invasive, accurate method for detecting genetic mutations and monitoring treatment responses, making it a valuable tool in hematologic cancer care.
  • AI-Driven Diagnostic Tools: The integration of artificial intelligence (AI) into molecular testing platforms presents a growth opportunity by enhancing diagnostic accuracy and speed. AI algorithms can analyze vast amounts of genetic data more effectively, leading to earlier detection of hematologic malignancies and better-informed treatment decisions.
  • Expansion of Testing Access: There is a significant growth opportunity in expanding access to molecular testing in underserved regions. Public-private partnerships, alongside government support, can help make these advanced diagnostic tools affordable and accessible in developing countries, improving early detection and treatment outcomes in blood cancer care.
  • Targeted Therapies Based on Molecular Profiling: Molecular testing is crucial for identifying biomarkers that guide targeted therapies. The ability to offer personalized treatment for hematologic cancers such as leukemia and lymphoma creates a growth opportunity for molecular testing companies, especially those focused on developing and integrating new therapies.

The strategic growth opportunities in the onco-hematology molecular testing market highlight the industry's potential to improve diagnostic accuracy, patient outcomes, and treatment options. From NGS and liquid biopsy advancements to AI integration and targeted therapies, these opportunities will drive significant market growth and better patient care in the years to come.

Onco-Hematology Molecular Testing Market Driver and Challenges

The global onco-hematology molecular testing market is influenced by several drivers and challenges, shaping its growth trajectory and adoption of advanced diagnostic technologies.

The factors responsible for driving the onco-hematology molecular testing market include:

1. Technological Advancements in Diagnostics: The development of next-generation sequencing (NGS), liquid biopsies, and AI has revolutionized molecular testing. These technologies allow for more accurate, comprehensive, and less invasive testing methods, driving market growth by improving diagnosis and personalized treatment for hematologic cancers.

2. Rising Demand for Personalized Medicine: There is a growing demand for personalized medicine in oncology and hematology, with molecular testing playing a critical role in identifying genetic mutations and tailoring treatments. This demand drives the adoption of molecular diagnostics, as patients and healthcare providers seek more effective and targeted treatment options.

3. Government Support for Healthcare Innovations: Governments around the world are investing in healthcare innovations, including molecular diagnostics. Regulatory frameworks, such as those in the U.S. and China, promote the approval and adoption of advanced molecular testing technologies, providing a favorable environment for market growth.

4. Increasing Awareness of Hematologic Cancer: As awareness of hematologic cancers like leukemia and lymphoma increases, more patients are seeking early diagnostic tests. This awareness is driving the demand for molecular testing, particularly in regions where healthcare infrastructure is improving.

5. Growing Healthcare Expenditure: Higher healthcare spending globally, especially in emerging markets, is making advanced diagnostic tools more accessible. As healthcare budgets increase, more funds are allocated to cancer research and diagnostics, boosting the molecular testing market.

Challenges in the onco-hematology molecular testing market are:

1. High Cost of Molecular Testing: One of the major challenges is the high cost of advanced molecular testing technologies, which can limit accessibility for patients, particularly in low- and middle-income countries. Despite advances in technology, affordability remains a significant barrier.

2. Regulatory and Reimbursement Issues: Regulatory hurdles and lack of consistent reimbursement policies in different countries can slow the adoption of molecular testing. Variations in regulatory approval timelines and reimbursement criteria hinder the widespread use of new diagnostic tools.

3. Limited Healthcare Infrastructure in Developing Regions: Although demand is rising in emerging markets, limited healthcare infrastructure and a lack of trained professionals pose challenges to the adoption of advanced molecular testing technologies in these regions. Overcoming these barriers is key to global market growth.

The drivers of technological innovation, government support, and increasing demand for personalized care are helping shape the growth of the onco-hematology molecular testing market. However, challenges related to cost, regulatory issues, and healthcare infrastructure limitations must be addressed to fully realize the potential of these innovations. Addressing these challenges will be essential for expanding access to cutting-edge diagnostic tools worldwide.

List of Onco-Hematology Molecular Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies onco-hematology molecular testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the onco-hematology molecular testing companies profiled in this report include-

  • Asuragen
  • Bio-Rad Laboratories
  • Illumina
  • QIAGEN
  • Cepheid

Onco-Hematology Molecular Testing Market by Segment

The study includes a forecast for the global onco-hematology molecular testing market by type, application, and region.

Onco-Hematology Molecular Testing Market by Type [Value from 2019 to 2031]:

  • qPCR
  • dPCR
  • Next-Generation Sequencing
  • Others

Onco-Hematology Molecular Testing Market by Application [Value from 2019 to 2031]:

  • National Reference Lab / Specialty Lab
  • University Hospital
  • Community Hospital

Onco-Hematology Molecular Testing Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Onco-Hematology Molecular Testing Market

The global onco-hematology molecular testing market is evolving rapidly due to innovations in technology, growing healthcare demands, and improvements in diagnostic techniques. Countries like the United States, China, Germany, India, and Japan are key players, contributing significantly to advancements in cancer and blood disorder testing. This market's developments reflect efforts to enhance early detection, personalized treatment options, and patient outcomes across diverse global healthcare landscapes.

  • United States: The U.S. is at the forefront of onco-hematology molecular testing, driven by significant investments in precision medicine. The country is witnessing increased adoption of next-generation sequencing (NGS) and liquid biopsy technologies. The FDA's approval of several molecular diagnostic tools for hematologic cancers has catalyzed the growth of this market. Moreover, collaboration between biotech companies and healthcare providers is accelerating the development of personalized treatment strategies for patients with leukemia, lymphoma, and other blood cancers.
  • China: China's onco-hematology molecular testing market is experiencing rapid growth due to increasing healthcare access and technological advancements. The government's emphasis on enhancing its healthcare infrastructure and funding cancer research is contributing to the adoption of molecular diagnostics. Chinese companies are also focusing on the development of affordable testing solutions, while collaborations with global players are helping to introduce cutting-edge technologies like NGS and gene editing tools to diagnose hematological malignancies more effectively.
  • Germany: Germany is a leader in Europe for onco-hematology molecular testing, supported by a strong healthcare system and robust R&D efforts. With a high level of adoption of advanced technologies like NGS and PCR-based tests, Germany is making strides in the molecular profiling of hematologic cancers. Moreover, German healthcare institutions are prioritizing the development of minimally invasive diagnostic methods, such as liquid biopsies, to detect genetic mutations and alterations in blood disorders early on.
  • India: India's onco-hematology molecular testing market is expanding as the healthcare sector modernizes. Key drivers include improved healthcare access, greater awareness of cancer and blood disorders, and an increase in affordable diagnostic options. India is also experiencing a rise in public and private collaborations focused on introducing molecular diagnostic tools for hematologic cancers. With the growing burden of cancer in the country, advancements in testing technology and genetic profiling are enhancing personalized treatment approaches.
  • Japan: Japan's onco-hematology molecular testing market benefits from strong government support and advanced technology. Japan is known for its robust healthcare infrastructure, allowing for the swift integration of molecular diagnostics into clinical practice. The country's focus on precision medicine is driving innovations in diagnostic technologies, such as liquid biopsies and targeted sequencing, enabling the identification of genetic mutations and optimizing treatment strategies for hematologic malignancies like leukemia and lymphoma.

Features of the Global Onco-Hematology Molecular Testing Market

  • Market Size Estimates: Onco-hematology molecular testing market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Onco-hematology molecular testing market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Onco-hematology molecular testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the onco-hematology molecular testing market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the onco-hematology molecular testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the onco-hematology molecular testing market by type (qPCR, dPCR, next-generation sequencing, and others), application (national reference lab / specialty lab, university hospital, and community hospital), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Onco-Hematology Molecular Testing Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 qPCR: Trends and Forecast (2019-2031)
  • 4.4 dPCR: Trends and Forecast (2019-2031)
  • 4.5 Next-Generation Sequencing: Trends and Forecast (2019-2031)
  • 4.6 Others: Trends and Forecast (2019-2031)

5. Global Onco-Hematology Molecular Testing Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 National Reference Lab / Specialty Lab: Trends and Forecast (2019-2031)
  • 5.4 University Hospital: Trends and Forecast (2019-2031)
  • 5.5 Community Hospital: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Onco-Hematology Molecular Testing Market by Region

7. North American Onco-Hematology Molecular Testing Market

  • 7.1 Overview
  • 7.2 North American Onco-Hematology Molecular Testing Market by type
  • 7.3 North American Onco-Hematology Molecular Testing Market by application
  • 7.4 United States Onco-Hematology Molecular Testing Market
  • 7.5 Mexican Onco-Hematology Molecular Testing Market
  • 7.6 Canadian Onco-Hematology Molecular Testing Market

8. European Onco-Hematology Molecular Testing Market

  • 8.1 Overview
  • 8.2 European Onco-Hematology Molecular Testing Market by type
  • 8.3 European Onco-Hematology Molecular Testing Market by application
  • 8.4 German Onco-Hematology Molecular Testing Market
  • 8.5 French Onco-Hematology Molecular Testing Market
  • 8.6 Spanish Onco-Hematology Molecular Testing Market
  • 8.7 Italian Onco-Hematology Molecular Testing Market
  • 8.8 United Kingdom Onco-Hematology Molecular Testing Market

9. APAC Onco-Hematology Molecular Testing Market

  • 9.1 Overview
  • 9.2 APAC Onco-Hematology Molecular Testing Market by type
  • 9.3 APAC Onco-Hematology Molecular Testing Market by application
  • 9.4 Japanese Onco-Hematology Molecular Testing Market
  • 9.5 Indian Onco-Hematology Molecular Testing Market
  • 9.6 Chinese Onco-Hematology Molecular Testing Market
  • 9.7 South Korean Onco-Hematology Molecular Testing Market
  • 9.8 Indonesian Onco-Hematology Molecular Testing Market

10. ROW Onco-Hematology Molecular Testing Market

  • 10.1 Overview
  • 10.2 ROW Onco-Hematology Molecular Testing Market by type
  • 10.3 ROW Onco-Hematology Molecular Testing Market by application
  • 10.4 Middle Eastern Onco-Hematology Molecular Testing Market
  • 10.5 South American Onco-Hematology Molecular Testing Market
  • 10.6 African Onco-Hematology Molecular Testing Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Onco-Hematology Molecular Testing Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Asuragen
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Bio-Rad Laboratories
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Illumina
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 QIAGEN
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Cepheid
    • Company Overview
    • Onco-Hematology Molecular Testing Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Onco-Hematology Molecular Testing Market
  • Figure 2.1: Usage of Onco-Hematology Molecular Testing Market
  • Figure 2.2: Classification of the Global Onco-Hematology Molecular Testing Market
  • Figure 2.3: Supply Chain of the Global Onco-Hematology Molecular Testing Market
  • Figure 3.1: Driver and Challenges of the Onco-Hematology Molecular Testing Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Onco-Hematology Molecular Testing Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Onco-Hematology Molecular Testing Market ($B) by Type
  • Figure 4.3: Forecast for the Global Onco-Hematology Molecular Testing Market ($B) by Type
  • Figure 4.4: Trends and Forecast for qPCR in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 4.5: Trends and Forecast for dPCR in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Next-Generation Sequencing in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Others in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 5.1: Global Onco-Hematology Molecular Testing Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Onco-Hematology Molecular Testing Market ($B) by Application
  • Figure 5.3: Forecast for the Global Onco-Hematology Molecular Testing Market ($B) by Application
  • Figure 5.4: Trends and Forecast for National Reference Lab / Specialty Lab in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 5.5: Trends and Forecast for University Hospital in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Community Hospital in the Global Onco-Hematology Molecular Testing Market (2019-2031)
  • Figure 6.1: Trends of the Global Onco-Hematology Molecular Testing Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Onco-Hematology Molecular Testing Market ($B) by Region (2025-2031)
  • Figure 7.1: North American Onco-Hematology Molecular Testing Market by type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American Onco-Hematology Molecular Testing Market ($B) by type (2019-2024)
  • Figure 7.3: Forecast for the North American Onco-Hematology Molecular Testing Market ($B) by type (2025-2031)
  • Figure 7.4: North American Onco-Hematology Molecular Testing Market by application in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American Onco-Hematology Molecular Testing Market ($B) by application (2019-2024)
  • Figure 7.6: Forecast for the North American Onco-Hematology Molecular Testing Market ($B) by application (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.1: European Onco-Hematology Molecular Testing Market by type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European Onco-Hematology Molecular Testing Market ($B) by type (2019-2024)
  • Figure 8.3: Forecast for the European Onco-Hematology Molecular Testing Market ($B) by type (2025-2031)
  • Figure 8.4: European Onco-Hematology Molecular Testing Market by application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European Onco-Hematology Molecular Testing Market ($B) by application (2019-2024)
  • Figure 8.6: Forecast for the European Onco-Hematology Molecular Testing Market ($B) by application (2025-2031)
  • Figure 8.7: Trends and Forecast for the German Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.1: APAC Onco-Hematology Molecular Testing Market by type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC Onco-Hematology Molecular Testing Market ($B) by type (2019-2024)
  • Figure 9.3: Forecast for the APAC Onco-Hematology Molecular Testing Market ($B) by type (2025-2031)
  • Figure 9.4: APAC Onco-Hematology Molecular Testing Market by application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC Onco-Hematology Molecular Testing Market ($B) by application (2019-2024)
  • Figure 9.6: Forecast for the APAC Onco-Hematology Molecular Testing Market ($B) by application (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 10.1: ROW Onco-Hematology Molecular Testing Market by type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW Onco-Hematology Molecular Testing Market ($B) by type (2019-2024)
  • Figure 10.3: Forecast for the ROW Onco-Hematology Molecular Testing Market ($B) by type (2025-2031)
  • Figure 10.4: ROW Onco-Hematology Molecular Testing Market by application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW Onco-Hematology Molecular Testing Market ($B) by application (2019-2024)
  • Figure 10.6: Forecast for the ROW Onco-Hematology Molecular Testing Market ($B) by application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African Onco-Hematology Molecular Testing Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Onco-Hematology Molecular Testing Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Onco-Hematology Molecular Testing Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Onco-Hematology Molecular Testing Market by Type
  • Figure 12.2: Growth Opportunities for the Global Onco-Hematology Molecular Testing Market by Application
  • Figure 12.3: Growth Opportunities for the Global Onco-Hematology Molecular Testing Market by Region
  • Figure 12.4: Emerging Trends in the Global Onco-Hematology Molecular Testing Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Onco-Hematology Molecular Testing Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Onco-Hematology Molecular Testing Market by Region
  • Table 1.3: Global Onco-Hematology Molecular Testing Market Parameters and Attributes
  • Table 3.1: Trends of the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 3.2: Forecast for the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Onco-Hematology Molecular Testing Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.4: Trends of qPCR in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.5: Forecast for qPCR in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.6: Trends of dPCR in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.7: Forecast for dPCR in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.8: Trends of Next-Generation Sequencing in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.9: Forecast for Next-Generation Sequencing in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 4.10: Trends of Others in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 4.11: Forecast for Others in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Onco-Hematology Molecular Testing Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 5.4: Trends of National Reference Lab / Specialty Lab in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 5.5: Forecast for National Reference Lab / Specialty Lab in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 5.6: Trends of University Hospital in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 5.7: Forecast for University Hospital in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 5.8: Trends of Community Hospital in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 5.9: Forecast for Community Hospital in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 7.1: Trends of the North American Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 7.2: Forecast for the North American Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various type in the North American Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various type in the North American Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various application in the North American Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various application in the North American Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.1: Trends of the European Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 8.2: Forecast for the European Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various type in the European Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various type in the European Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various application in the European Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various application in the European Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.1: Trends of the APAC Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 9.2: Forecast for the APAC Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various type in the APAC Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various type in the APAC Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various application in the APAC Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various application in the APAC Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 10.1: Trends of the ROW Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 10.2: Forecast for the ROW Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various type in the ROW Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various type in the ROW Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various application in the ROW Onco-Hematology Molecular Testing Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various application in the ROW Onco-Hematology Molecular Testing Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Onco-Hematology Molecular Testing Market (2019-2031)
  • Table 11.1: Product Mapping of Onco-Hematology Molecular Testing Suppliers Based on Segments
  • Table 11.2: Operational Integration of Onco-Hematology Molecular Testing Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Onco-Hematology Molecular Testing Revenue
  • Table 12.1: New Product Launches by Major Onco-Hematology Molecular Testing Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Onco-Hematology Molecular Testing Market